Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is

Bromodomain and extraterminal (BET) domain inhibitors (BETis) show efficacy on NUT midline carcinoma (NMC). However, not all NMC patients respond, and responders eventually develop resistance and relapse. Using CRISPR and ORF expression screens, we systematically examined the ability of cancer drive...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Sida, Maertens, Ophélia, Cichowski, Karen, Elledge, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120715/
https://www.ncbi.nlm.nih.gov/pubmed/30135075
http://dx.doi.org/10.1101/gad.315648.118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120715/
https://www.ncbi.nlm.nih.gov/pubmed/30135075
http://dx.doi.org/10.1101/gad.315648.118

Ejemplares similares